Abstract
Objective
Test the hypothesis that soy isoflavone supplementation preserves bone mineral density
(BMD) in men and women.
Methods
We conducted a controlled, parallel-arm, double-blinded trial with 145 participants,
50–80 years, with random assignment to soy beverage daily for 12 months. Active treatment
(+ISO) received soy protein containing 83 mg isoflavones (45.6 mg genistein, 31.7 mg daidzein), aglycone units; the comparison group (−ISO) received soy protein containing
3 mg isoflavones. We measured BMD using dual-energy X-ray absorptiometry at the total
hip and posterior–anterior spine (L1–L4) at baseline in 22 women and 123 men, and
at 12 months in 13 women and 98 men. We used linear mixed models to test for an isoflavone
effect on percentage BMD change from baseline in spine and hip.
Results
Among all participants, mean percent change in spine BMD (±S.E.) was 0.16 ± 0.44 in −ISO (P = 0.10) at 12 months. Treatment effects on spine BMD were significantly greater in women
than men (P = 0.01). At 12 months, in women, mean percent change was 0.58 ± 0.70 in +ISO and −1.84 ± 0.86 in −ISO (P = 0.05); among men it was 1.32 ± 0.53 in +ISO and 0.31 ± 0.48 in −ISO (P = 0.16). By comparison, percent change in hip BMD was similar in the treatment groups,
and was not different between men and women. Mean percent change in hip BMD from baseline
to 12 months was 0.54 ± 0.38 in +ISO and −0.13 ± 0.36 in −ISO (P = 0.20) among all participants.
Conclusions
Soy protein containing isoflavones showed a modest benefit in preserving spine, but
not hip BMD in older women.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Effects of soy protein supplementation on spine and hip bone mineral density in an older population in a randomized controlled trial.J Nutr. 2004; 134: 1289S
- Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.JAMA. 1998; 280: 605-613
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.JAMA. 2004; 291: 1701-1712
- Prevalence of low femoral bone density in older U S. adults from NHANES III.J Bone Miner Res. 1997; 12: 1761-1768
- Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos).Osteoporos Int. 2000; 11: 897-904
- Male osteoporosis: epidemiology and pathophysiology.Curr Osteoporos Rep. 2003; 1: 71-77
- Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology.Eur J Endocrinol. 2006; 154: 175-185
- Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.J Clin Endocrinol Metab. 2001; 86: 3555-3561
- A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.J Bone Miner Res. 1998; 13: 763-773
- Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study.J Bone Miner Res. 1997; 12: 1833-1843
- Genetics of male osteoporosis.Calcif Tissue Int. 2001; 69: 200-204
- Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data.Curr Opin Clin Nutr Metab Care. 2004; 7: 649-658
- Soy isoflavones may protect against orchidectomy-induced bone loss in aged male rats.Calcif Tissue Int. 2005; 76: 56-62
- Modulation of age-related hyperparathyroidism and senile bone loss in Fischer rats by soy protein and food restriction.Endocrinology. 1988; 122: 1847-1854
- Genistein, a soybean isoflavone, affects bone marrow lymphopoiesis and prevents bone loss in castrated male mice.Bone. 2002; 31: 180-185
- Combined intervention of exercise and genistein prevented androgen deficiency-induced bone loss in mice.J Appl Physiol. 2003; 94: 335-342
- Soy protein containing isoflavones does not decrease colorectal epithelial cell proliferation in a randomized controlled trial.Am J Clin Nutr. 2005; 82: 620-626
- Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial.J Nutr. 2003; 133: 1316-1319
- Design of the fracture intervention trial.Osteoporos Int. 1993; 3: S29-S39
- Decreased bone resorption with soy isoflavone supplementation in postmenopausal women.J Womens Health (Larchmt). 2004; 13: 1000-1007
- Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women.Am J Clin Nutr. 2000; 72: 844-852
- The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial.Am J Clin Nutr. 2004; 79: 326-333
- The bone organ system: form and function.in: Osteoporosis. vol. 1. Academic Press, San Diego2001: 3-20 (Chapter 1)
- Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial.Menopause. 2004; 11: 246-254
- Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism.J Nutr. 2002; 132: 2605-2608
- Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women.Am J Clin Nutr. 1998; 68: 1375S-1379S
- Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial.Maturitas. 2002; 42: 295-300
- Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density.J Reprod Med. 2001; 46: 221-226
Article info
Publication history
Accepted:
April 15,
2006
Received in revised form:
April 12,
2006
Received:
August 19,
2005
Footnotes
☆Presented at the Fifth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, September 2003, Orlando, FL [
[1]
].Identification
Copyright
© 2006 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
